NYSEARCA:VTAK - NYSE Arca - US74933X6094 - Common Stock - Currency: USD
0.365
-0.06 (-15.12%)
The current stock price of VTAK is 0.365 USD. In the past month the price increased by 19.71%. In the past year, price decreased by -93.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.37 | 235.96B | ||
ISRG | INTUITIVE SURGICAL INC | 67.04 | 183.58B | ||
BSX | BOSTON SCIENTIFIC CORP | 36.94 | 147.56B | ||
SYK | STRYKER CORP | 30.11 | 144.19B | ||
MDT | MEDTRONIC PLC | 15.87 | 111.93B | ||
BDX | BECTON DICKINSON AND CO | 12.22 | 49.36B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.9 | 44.08B | ||
IDXX | IDEXX LABORATORIES INC | 45.85 | 42.36B | ||
RMD | RESMED INC | 27.46 | 36.56B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.71 | 33.08B | ||
DXCM | DEXCOM INC | 49.69 | 32.15B | ||
STE | STERIS PLC | 25.84 | 23.71B |
Catheter Precision, Inc. engages in the design, manufacture and sale of medical devices and technologies for cardiac electrophysiology. The company is headquartered in Fort Mill, South Carolina and currently employs 22 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The firm's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. The company is developing a kit of tools to enable physicians to gain access to the pericardial space of the heart.
CATHETER PRECISION INC
1670 Highway 160 West, Suite 205
Fort Mill SOUTH CAROLINA US
Employees: 22
Phone: 19736912000
The current stock price of VTAK is 0.365 USD. The price decreased by -15.12% in the last trading session.
The exchange symbol of CATHETER PRECISION INC is VTAK and it is listed on the NYSE Arca exchange.
VTAK stock is listed on the NYSE Arca exchange.
7 analysts have analysed VTAK and the average price target is 2.04 USD. This implies a price increase of 458.9% is expected in the next year compared to the current price of 0.365. Check the CATHETER PRECISION INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CATHETER PRECISION INC (VTAK) has a market capitalization of 4.02M USD. This makes VTAK a Nano Cap stock.
CATHETER PRECISION INC (VTAK) currently has 22 employees.
The Revenue of CATHETER PRECISION INC (VTAK) is expected to grow by 533.33% in the next year. Check the estimates tab for more information on the VTAK EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VTAK does not pay a dividend.
CATHETER PRECISION INC (VTAK) will report earnings on 2025-08-12, after the market close.
CATHETER PRECISION INC (VTAK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.08).
The outstanding short interest for CATHETER PRECISION INC (VTAK) is 2.2% of its float. Check the ownership tab for more information on the VTAK short interest.
ChartMill assigns a technical rating of 5 / 10 to VTAK. When comparing the yearly performance of all stocks, VTAK is a bad performer in the overall market: 95.9% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to VTAK. VTAK may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months VTAK reported a non-GAAP Earnings per Share(EPS) of -9.08. The EPS decreased by -18.23% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -93.43% | ||
ROE | -292.71% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 86% to VTAK. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 29.21% and a revenue growth 533.33% for VTAK